ICCC— IMMUCELL CORP /DE/

MaterialsBiotechnology$100M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Product sales	$27.6M+4.3%	$26.5M+51.6%	$17.5M-5.9%	$18.6M
Costs of goods sold	$16.2M-12.7%	$18.6M+36.4%	$13.6M+24.6%	$10.9M
Gross profit	$11.4M+44.1%	$7.9M+105.2%	$3.9M-49.4%	$7.6M
Product development expenses	$3.0M-22.0%	$3.9M-11.3%	$4.4M-2.2%	$4.5M
Sales and marketing expenses	$3.6M+2.5%	$3.5M+12.2%	$3.1M-3.2%	$3.2M
Administrative expenses	$3.2M+44.4%	$2.2M+3.9%	$2.1M-5.7%	$2.3M
Operating expenses	$9.8M+2.2%	$9.6M-0.4%	$9.6M-3.3%	$9.9M
NET OPERATING INCOME (LOSS)	$1.6M+200.6%	-$1.6M+71.5%	-$5.7M-150.0%	-$2.3M
Other expenses, net	$2.7M+428.8%	$506K+2213.1%	$22K-88.3%	$187K
LOSS BEFORE INCOME TAXES	-$1.0M+52.1%	-$2.1M+62.8%	-$5.8M-132.1%	-$2.5M
Income tax expense	$12K+15.1%	$10K+117.3%	$5K-39.7%	$8K
NET LOSS	-$1.0M+51.8%	-$2.2M+62.7%	-$5.8M-131.6%	-$2.5M
Basic weighted average common shares outstanding (in shares)	9.0M+10.5%	8.2M+5.4%	7.7M+0.0%	7.7M
Basic net loss per share (in dollars per share)	-$0.12+53.8%	-$0.26+65.3%	-$0.75-134.4%	-$0.32
Diluted weighted average common shares outstanding (in shares)	9.0M+10.5%	8.2M+5.4%	7.7M+0.0%	7.7M
Diluted net loss per share (in dollars per share)	-$0.12+53.8%	-$0.26+65.3%	-$0.75-134.4%	-$0.32

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.